Search

Objective: To determine the efficiency of our vitrification technique when applied in young fertile women. Design: Clinical research and application. Setting: In vitro fertilization center. Patient(s): Twenty-one women were recruited from the navy community with 19 patients finishing the study. Intervention(s): Vitrified oocytes with use of the electron microscopic grid method were warmed 6 months after vitrification. Surviving metaphase II oocytes were microinjected for fertilization, and clinical results were evaluated. Main Outcome Measure(s): Survival, fertilization, and cleavage rate. Pregnancy and implantation rate. Result(s): Three hundred ninety-five oocytes were warmed, of which 320 oocytes (81.0%) survived. Two hundred eighty-five metaphase II oocytes were microinjected for fertilization; 206 of them (72.3%) fertilized, and 53 embryos were transferred to 19 patients (in 20 warming cycles). Twenty-four of 53 transferred embryos (45.3%) implanted as confirmed by ultrasound examination. Of the 20 transfers, 16 resulted in clinical pregnancy (80%), 3 miscarried (15%), and 13 (65%) went on to produce 20 live births, respectively. This is much higher in comparison with our previous data using supernumerary oocytes where the rates of implantation and pregnancy were 6% and 21%. Live-birth rates per warmed oocyte and per injected oocyte were 5.1% and 7.2%, respectively. Conclusion(s): High pregnancy and implantation rates were observed after 6 months of cryopreservation by vitrification when oocytes from fertile woman were used. Proper screening of candidates for oocyte cryopreservation is of crucial importance to assure a favorable pregnancy outcome. [Copyright &y& Elsevier]

We conducted a retrospective review of all frozen ETs from May 2002 to October 2007 using our new vitrification technique in order to determine its efficacy. We found high pregnancy (70.5%; 79/112) and implantation (40.6%; 110/271) rates with the use of this new method. [Copyright &y& Elsevier]

Objective To determine whether endometrial hCG infusion at the time of human blastocyst transfer impacts implantation rates. Design Randomized double-blinded placebo-controlled trial. Setting Academic. Patient(s) Infertile couples with the female partner less than 43 years old (n = 300) undergoing fresh or frozen ET of one or two blastocysts. Intervention(s) Patients undergoing ET were randomized into either a treatment or a control group. The treatment group received an infusion of 500 IU of hCG diluted in ET media. The control group received a sham infusion of ET media. Infusions were done using a separate catheter less than 3 minutes before actual ET. Main Outcome Measure(s) Sustained implantation rate: ongoing viable gestation (primary outcome) and ongoing pregnancy rate (secondary outcome). Result(s) A total of 473 blastocysts were transferred into 300 patients. There were no differences between the two groups in sustained implantation rate (48.1% in the hCG group, 44.2% in the control group) or ongoing pregnancy rate (58.8% in the hCG group, 52.0% in the control group). Conclusion(s) Endometrial infusion of hCG at the time of blastocyst ET does not improve sustained implantation rates. Clinical Trial Registration Number NCT01643993 . [ABSTRACT FROM AUTHOR]